Boston Biomedical Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Boston Biomedical's estimated annual revenue is currently $8.4M per year.(i)
  • Boston Biomedical's estimated revenue per employee is $201,000

Employee Data

  • Boston Biomedical has 42 Employees.(i)
  • Boston Biomedical grew their employee count by -12% last year.

Boston Biomedical's People

NameTitleEmail/Phone
1
Medical DirectorReveal Email/Phone
2
Executive Director and Head, Clinical Pharmacology and Drug MetabolismReveal Email/Phone
3
Executive Medical Director Clinical ResearchReveal Email/Phone
4
Director AccountingReveal Email/Phone
5
Senior DirectorReveal Email/Phone
6
Chief Operating OfficerReveal Email/Phone
7
Senior Director Program ManagementReveal Email/Phone
8
Clinical Data ManagerReveal Email/Phone
9
Senior Manager, Marketing SupportReveal Email/Phone
10
Principal BiostatisticianReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.6M21719%N/AN/A
Add Company

What Is Boston Biomedical?

Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company's range of expertise includes drug discovery, external innovation partnerships, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs and commercialization. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. has created a unique corporate environment, leveraging its innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for patients with cancer. Visit https://www.bostonbiomedical.com/careers/ for more information. Boston Biomedical, Inc. is indirectly and wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. In 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma's global oncology and hematology portfolios. Together, the companies Sumitomo Dainippon Pharma Co., Ltd., Boston Biomedical and Tolero Pharmaceuticals work to expedite drug discovery, development and commercialization of innovative treatments for cancer. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

N/A

Total Funding

42

Number of Employees

$8.4M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Boston Biomedical News

2022-04-20 - Global Peptide Cancer Vaccine Market Research Report 2022 ...

Generex Biotechnology Corporation; Boston Biomedical; OncoTherapy Science; BrightPath Biotherapeutics; Enzo Life Science. Report Findings. 1)...

2022-04-17 - Peptide Cancer Vaccine Market Size And Forecast | Boston ...

Boston Biomedical, VAXON Biotech, TapImmune, Sellas, ISA Pharmaceuticals, Generex Biotechnology, Immatics, OncoTherapy Science,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M4220%$176.5M
#2
$9.1M42-21%N/A
#3
$3.4M4220%N/A
#4
$4.7M425%N/A
#5
$4.7M42-7%N/A